195 related articles for article (PubMed ID: 7989949)
1. Renal dysfunction associated with the administration of high-dose interleukin-2 in 199 consecutive patients with metastatic melanoma or renal carcinoma.
Guleria AS; Yang JC; Topalian SL; Weber JS; Parkinson DR; MacFarlane MP; White RL; Steinberg SM; White DE; Einhorn JH
J Clin Oncol; 1994 Dec; 12(12):2714-22. PubMed ID: 7989949
[TBL] [Abstract][Full Text] [Related]
2. Decreased tolerance to interleukin-2 with repeated courses of therapy in patients with metastatic melanoma or renal cell cancer.
Marroquin CE; White DE; Steinberg SM; Rosenberg SA; Schwartzentruber DJ
J Immunother; 2000; 23(3):387-92. PubMed ID: 10838668
[TBL] [Abstract][Full Text] [Related]
3. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2.
Rosenberg SA; Yang JC; Topalian SL; Schwartzentruber DJ; Weber JS; Parkinson DR; Seipp CA; Einhorn JH; White DE
JAMA; 1994 Mar 23-30; 271(12):907-13. PubMed ID: 8120958
[TBL] [Abstract][Full Text] [Related]
4. Impact of the number of treatment courses on the clinical response of patients who receive high-dose bolus interleukin-2.
Lindsey KR; Rosenberg SA; Sherry RM
J Clin Oncol; 2000 May; 18(9):1954-9. PubMed ID: 10784637
[TBL] [Abstract][Full Text] [Related]
5. The hematologic toxicity of interleukin-2 in patients with metastatic melanoma and renal cell carcinoma.
MacFarlane MP; Yang JC; Guleria AS; White RL; Seipp CA; Einhorn JH; White DE; Rosenberg SA
Cancer; 1995 Feb; 75(4):1030-7. PubMed ID: 7842405
[TBL] [Abstract][Full Text] [Related]
6. Prospective randomized trial of lisofylline for the prevention of toxicities of high-dose interleukin 2 therapy in advanced renal cancer and malignant melanoma.
Margolin K; Atkins M; Sparano J; Sosman J; Weiss G; Lotze M; Doroshow J; Mier J; O'Boyle K; Fisher R; Campbell E; Rubin J; Federighi D; Bursten S
Clin Cancer Res; 1997 Apr; 3(4):565-72. PubMed ID: 9815721
[TBL] [Abstract][Full Text] [Related]
7. Results of two sequential phase II studies of interleukin-2 (IL2) in metastatic renal cell carcinoma and melanoma: high-dose continuous intravenous IL2 infusion and subcutaneous IL2 administration in combination with alpha interferon.
Hidalgo OF; AramendÃa JM; Alonso G; Foncillas JG; Brugarolas A
Rev Med Univ Navarra; 1996; 40(3):6-12. PubMed ID: 9499820
[TBL] [Abstract][Full Text] [Related]
8. Randomized comparison of high-dose and low-dose intravenous interleukin-2 for the therapy of metastatic renal cell carcinoma: an interim report.
Yang JC; Topalian SL; Parkinson D; Schwartzentruber DJ; Weber JS; Ettinghausen SE; White DE; Steinberg SM; Cole DJ; Kim HI
J Clin Oncol; 1994 Aug; 12(8):1572-6. PubMed ID: 8040669
[TBL] [Abstract][Full Text] [Related]
9. Immune effects of escalating doses of granulocyte-macrophage colony-stimulating factor added to a fixed, low-dose, inpatient interleukin-2 regimen: a randomized phase I trial in patients with metastatic melanoma and renal cell carcinoma.
Smith II JW; Kurt RA; Baher AG; Denman S; Justice L; Doran T; Gilbert M; Alvord WG; Urba WJ
J Immunother; 2003; 26(2):130-8. PubMed ID: 12616104
[TBL] [Abstract][Full Text] [Related]
10. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy.
Fyfe G; Fisher RI; Rosenberg SA; Sznol M; Parkinson DR; Louie AC
J Clin Oncol; 1995 Mar; 13(3):688-96. PubMed ID: 7884429
[TBL] [Abstract][Full Text] [Related]
11. Radiotherapy and High-Dose Interleukin-2: Clinical and Immunological Results of a Proof of Principle Study in Metastatic Melanoma and Renal Cell Carcinoma.
Bulgarelli J; Piccinini C; Petracci E; Pancisi E; Granato AM; de Rosa F; Guidoboni M; Petrini M; Ancarani V; Foschi G; Romeo A; Tontini L; De Giorgi U; Lolli C; Gentili G; Valmorri L; Rossi A; Ferroni F; Casadei C; Cortesi P; Crudi L; Ridolfi L
Front Immunol; 2021; 12():778459. PubMed ID: 34777395
[TBL] [Abstract][Full Text] [Related]
12. Combination therapy with interferon alfa-2a and interleukin-2 for the treatment of metastatic cancer.
Marincola FM; White DE; Wise AP; Rosenberg SA
J Clin Oncol; 1995 May; 13(5):1110-22. PubMed ID: 7738617
[TBL] [Abstract][Full Text] [Related]
13. High-dose continuous intravenous infusion of interleukin-2 therapy for metastatic renal cell carcinoma: the University of Chicago experience.
Shulman KL; Stadler WM; Vogelzang NJ
Urology; 1996 Feb; 47(2):194-7. PubMed ID: 8607232
[TBL] [Abstract][Full Text] [Related]
14. A randomized phase II trial of continuous infusion interleukin-2 or bolus injection interleukin-2 plus lymphokine-activated killer cells for advanced renal cell carcinoma.
Weiss GR; Margolin KA; Aronson FR; Sznol M; Atkins MB; Dutcher JP; Gaynor ER; Boldt DH; Doroshow JH; Bar MH
J Clin Oncol; 1992 Feb; 10(2):275-81. PubMed ID: 1732429
[TBL] [Abstract][Full Text] [Related]
15. Phase IB clinical trial of anti-CD3 followed by high-dose bolus interleukin-2 in patients with metastatic melanoma and advanced renal cell carcinoma: clinical and immunologic effects.
Sosman JA; Weiss GR; Margolin KA; Aronson FR; Sznol M; Atkins MB; O'Boyle K; Fisher RI; Boldt DH; Doroshow J
J Clin Oncol; 1993 Aug; 11(8):1496-505. PubMed ID: 8336188
[TBL] [Abstract][Full Text] [Related]
16. Trends in the safety of high dose bolus interleukin-2 administration in patients with metastatic cancer.
Kammula US; White DE; Rosenberg SA
Cancer; 1998 Aug; 83(4):797-805. PubMed ID: 9708948
[TBL] [Abstract][Full Text] [Related]
17. Renal toxicity of interleukin-2 administration in patients with metastatic renal cell cancer: effect of pre-therapy nephrectomy.
Belldegrun A; Webb DE; Austin HA; Steinberg SM; Linehan WM; Rosenberg SA
J Urol; 1989 Mar; 141(3):499-503. PubMed ID: 2783983
[TBL] [Abstract][Full Text] [Related]
18. Strategies to reduce side effects of interleukin-2: evaluation of the antihypotensive agent NG-monomethyl-L-arginine.
Kilbourn RG; Fonseca GA; Trissel LA; Griffith OW
Cancer J Sci Am; 2000 Feb; 6 Suppl 1():S21-30. PubMed ID: 10685654
[TBL] [Abstract][Full Text] [Related]
19. Activity of continuous infusion plus pulse interleukin-2 with famotidine in patients with metastatic kidney cancer or melanoma previously treated with interleukin-2.
Quan WD; Walker PR; Quan FM; Ramirez M; Elsamaloty HM; Ghai V; Vinogradov M; Liles DK
Cancer Biother Radiopharm; 2006 Oct; 21(5):437-42. PubMed ID: 17105418
[TBL] [Abstract][Full Text] [Related]
20. Phase I trial of sequential low-dose 5-aza-2'-deoxycytidine plus high-dose intravenous bolus interleukin-2 in patients with melanoma or renal cell carcinoma.
Gollob JA; Sciambi CJ; Peterson BL; Richmond T; Thoreson M; Moran K; Dressman HK; Jelinek J; Issa JP
Clin Cancer Res; 2006 Aug; 12(15):4619-27. PubMed ID: 16899610
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]